3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Myasthenia Gravis
1
Interventions
Specimen Handling
613
pembrolizumab
583
Magnetic Resonance Spectroscopy
543
Carboplatin
430
Cyclophosphamide
380
Cisplatin
377
Biopsy
366
Paclitaxel
314
Nivolumab
312
Gemcitabine
308
Radiotherapy
268
Bevacizumab
230
Dexamethasone
217
fludarabine
205
Docetaxel
190
durvalumab
188
venetoclax
187
Oxaliplatin
187
Rituximab
174
Fluorouracil
174
atezolizumab
169
Pemetrexed
166
Capecitabine
162
Radiosurgery
160
Doxorubicin
160
Radiation
156
Ipilimumab
144
Lenalidomide
140
Leucovorin
138
Etoposide
134
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
efgartigimod alfa
×
90 days
×
Clear all
NCT07217587
2026-05-08
EPIC
Janssen Research & Development, LLC
Phase 3
Recruiting
115 enrolled